← Oncology Approval Tracker

FDA DECISION ·

Lynparza

olaparib · AstraZeneca

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant treatment for adults with high-risk, HER2-negative early breast cancer and a deleterious or suspected deleterious germline BRCA mutation after neoadjuvant or adjuvant chemotherapy.

LAMPGEN ANALYSIS

Why it matters

This brings PARP inhibition to an early breast cancer setting defined by inherited BRCA status and risk.

What research teams should watch

Verify germline testing and document high-risk features, local treatment, and prior chemotherapy.

PRIMARY RECORDS

Sources